Drug intelligence / Profile preview

Weibing IV

Development stage: Phase 1
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Weibing IV is a Traditional Chinese Medicine (TCM) formula developed by the Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University. It is one of four syndrome-differentiated formulae (Weibing I, II, III, and IV) evaluated in clinical trials for the treatment of functional dyspepsia. The treatment approach is based on TCM principles of differentiating between cold and heat, as well as asthenia (deficiency) and sthenia (excess) patterns. Weibing IV is specifically designed to address one of these four quadrants of syndrome differentiation to improve gastric symptoms and regulate gastrointestinal function. The formula typically consists of a combination of botanical ingredients tailored to the specific TCM syndrome pattern identified in the patient.

Other names: Weibing 4Weibing4Weibing-4Weibing No. 4

Beyond the preview

Go deeper on Weibing IV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weibing IV.